BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 15606727)

  • 1. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
    Tsuboi K; Yamamoto H
    Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22498845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data.
    Dehout F; Schwarting A; Beck M; Mehta A; Ricci R; Widmer U;
    Acta Paediatr Suppl; 2003 Dec; 92(443):14-5; discussion 5. PubMed ID: 14989460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
    Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
    Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
    Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
    Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.
    Mehta A; Beck M; Elliott P; Giugliani R; Linhart A; Sunder-Plassmann G; Schiffmann R; Barbey F; Ries M; Clarke JT;
    Lancet; 2009 Dec; 374(9706):1986-96. PubMed ID: 19959221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).
    Tsuboi K; Yamamoto H
    Genet Med; 2012 Sep; 14(9):779-86. PubMed ID: 22878505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of agalsidase alfa in patients with Fabry disease under 7 years.
    Ramaswami U; Parini R; Kampmann C; Beck M
    Acta Paediatr; 2011 Apr; 100(4):605-11. PubMed ID: 21114524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.